Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2015-02-13
Target enrollment:
Participant gender:
Summary
This research is being done because it is not yet known what dose of foretinib in combination
with lapatinib can be given safely to patients with breast cancer, nor what type and severity
of side effects will result from the combination of the two treatments. This research is also
being done because it is not clear if the addition of the new drug foretinib to treatment
with lapatinib can offer better results and longer survival than treatment with lapatinib
alone.